Colorectal cancer treatment resistance : mechanisms, insights, advances and solutions /
Colorectal Cancer Treatment Resistance: Mechanisms, Insights, Advances and Solutions provide insights, knowledge, and potential solutions for healthcare professionals, researchers, and individuals affected by colorectal cancer.
সংরক্ষণ করুন:
| অন্যান্য লেখক: | |
|---|---|
| বিন্যাস: | বৈদ্যুতিন গ্রন্থ |
| ভাষা: | ইংরেজি |
| প্রকাশিত: |
London, United Kingdom :
Academic Press,
2025.
|
| বিষয়গুলি: | |
| অনলাইন ব্যবহার করুন: | ScienceDirect |
| ট্যাগগুলো: |
ট্যাগ যুক্ত করুন
কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!
|
MARC
| LEADER | 00000cam a22000007a 4500 | ||
|---|---|---|---|
| 001 | on1467957548 | ||
| 003 | OCoLC | ||
| 005 | 20260915095216.0 | ||
| 006 | m d | ||
| 007 | cr ||||||||||| | ||
| 008 | 241111s2025 enk o 001 0 eng d | ||
| 040 | |a YDX |b eng |c YDX |d OPELS |d N$T |d OCLCO |d OCLCQ |d OCLCL |d SFB |d OCLCF |d OCLCO | ||
| 020 | |a 0443334765 |q (electronic bk.) | ||
| 020 | |a 9780443334764 |q (electronic bk.) | ||
| 020 | |z 9780443334757 | ||
| 035 | |a (OCoLC)1467957548 | ||
| 050 | 4 | |a RC280.C6 | |
| 082 | 0 | 4 | |a 616.99/4347061 |2 23/eng/20241120 |1 https://id.oclc.org/worldcat/ddc/E3vRfdTrxVpF66hH6TBdvKgdBh |
| 245 | 0 | 0 | |a Colorectal cancer treatment resistance : |b mechanisms, insights, advances and solutions / |c edited by Zodwa Dlamini. |
| 260 | |a London, United Kingdom : |b Academic Press, |c 2025. | ||
| 300 | |a 1 online resource | ||
| 500 | |a Includes index. | ||
| 505 | 0 | |a Front Cover -- Colorectal Cancer Treatment Resistance -- Copyright Page -- Contents -- List of contributors -- Preface -- Part 1: Understanding Colorectal Cancer Drug Resistance -- Part 2: Innovative Approaches to Overcoming Drug Resistance -- Part 3: Molecular Factors and Therapeutic Strategies -- Part 4: Future Perspectives and Advanced Research -- 1 Understanding colorectal cancer drug resistance -- 1 Unraveling the mystery of treatment resistance in colorectal cancer -- Abbreviations -- Introduction -- Drug resistance in colorectal cancer -- Future technologies in overcoming treatment resistance -- Overcoming treatment resistance -- Chemotherapy resistance -- Immunotherapy and immunomodulation in treatment resistance -- Targeting alternative splicing -- Nanomedicine -- ncRNA in reversing resistance in colorectal cancer -- Targeting genetic signatures in overcoming colorectal cancer resistance -- Surgical interventions -- Research advances in colorectal treatment resistance -- Microbes in colon cancer drug resistance -- Conclusion -- Conflicts of interest -- References -- 2 Mechanisms of treatment resistance in colorectal cancer -- Abbreviations -- Introduction -- Multifaceted mechanisms underlying treatment resistance -- Role of pharmacokinetics in the evolution of treatment resistance -- Increased drug excretion -- Drug target alteration -- DNA damage repair -- The role of tumor microenvironment stromal cells in the evolution of treatment-resistant colorectal cancer -- Mesenchymal stem cells -- Cancer-associated fibroblasts -- Immunosuppressive cells -- The role of adipocytes -- Why do certain therapies fail? -- Potential targets for intervention to overcome resistance -- Limitations -- Conclusion -- Conflict of interest -- References -- 3 Biomarkers and predictive factors in colorectal cancer treatment resistance -- Abbreviations. | |
| 505 | 8 | |a Introduction -- Biomarkers in colorectal cancer diagnosis, prognosis, therapy, and response -- Diagnostic biomarkers in colorectal cancer -- Prognostic biomarkers in colorectal cancer -- Predictive biomarkers in colorectal cancer -- Predictive factors in colorectal cancer treatment resistance -- Hypermethylation -- Tumor microenvironment -- Other factors -- Colorectal cancer exposome and disparities -- Effects of ecosystems on colorectal cancer -- Lifestyles factors and colorectal cancer -- Social variables and colorectal cancer -- Advances and integrated approaches in colorectal cancer prognostic biomarker discovery -- Genomics -- Proteomics -- Metabolomics -- Multiomics approaches -- Challenges and limitations -- Conclusions -- Conflict of interest -- References -- 4 Targeted therapies and precision medicine in colorectal cancer drug resistance -- List of abbreviations -- Introduction -- Innovative approaches that tailor treatments to the unique genetic and molecular characteristics -- Ground-breaking advances in precision medicine and FDA-accepted targeted therapies -- Bevacizumab -- Cetuximab -- Panitumumab -- Ziv-Aflibercept -- Regorafenib -- Ramucirumab -- Pembrolizumab -- Nivolumab -- Ipilimumab -- Encorafenib -- Molecular pathways of colorectal cancer and potential targeted therapies -- Rat sarcoma-mutation targeted therapy -- Serine/threonine-protein kinase B-Raf mutation targeted therapy -- Microsatellite Instability targeted therapy -- Neurotrophic tyrosine receptor kinase gene fusion targeted therapy -- The role of phytochemical-based targeted therapy in colorectal cancer -- Combination therapy measures -- Limitations -- Conclusion -- Conflicts of interest -- References -- 2 Innovative approaches to overcoming drug resistance -- 5 Overcoming chemotherapy resistance in colorectal cancer -- Abbreviations. | |
| 505 | 8 | |a Introduction into colorectal cancer -- Strategies to overcome chemotherapy resistance in colorectal cancer -- Medications and supplements -- Metformin -- Ivermectin -- Dichloroacetate -- Bazedoxifene -- Enalapril -- Melatonin -- Vitamins -- S-adenosylmethionine -- Nonsteroidal antiinflammatory drugs -- Gene therapy -- Ribozymes -- RNA interference -- Antisense oligonucleotides -- Clustered regularly interspaced short palindromic repeats -- Epigenetic therapy -- Noncoding RNAs -- Protein inhibitors -- Inhibitors of common resistance-related proteins -- Epidermal growth factor receptor inhibitors -- Sphingosine 1 phosphate receptor modulators -- Natural herbal compounds -- Innovative drug delivery system -- Liposomes -- Hydrogels -- Nanocarriers -- Exosomes -- Combinational therapy -- Supportive care measures -- Limitations -- Conclusion -- Conflict of Interest -- References -- 6 Emerging treatment approaches for colorectal cancer treatment resistance -- Abbreviations -- Introduction -- Targeted therapies -- Epidermal growth factor receptor inhibitors -- Antiangiogenic agents -- Human epidermal growth factor receptor 2-targeted therapies -- BRAF inhibitors -- Mismatch repair and microsatellite instability targeting -- PI3K/AKT/mTOR pathway inhibitors -- Wnt pathway inhibitors -- Human epidermal growth factor receptor 3-targeted therapies -- Immunotherapies -- Immune checkpoint inhibitors and the MSI-H/dMMR subset -- Expanding immunotherapy to microsatellite stable colorectal cancer -- Personalized vaccines and neoantigen targeting -- Chimeric antigen receptor T-cell therapy -- Bispecific antibodies and T-cell engagers -- Microbiome modulation and response to immunotherapy -- Combination therapies -- Personalized medicine strategies -- Limitations and outlook -- Conclusion -- Conflict of Interest -- References. | |
| 505 | 8 | |a 7 Immunotherapy and immunomodulation in colorectal cancer treatment resistance -- Abbreviations -- Introduction -- Current immunotherapeutic strategies in metastatic colorectal cancer management -- Understanding immunotherapy resistance mechanisms in colorectal cancer -- Immunotherapy strategies for overcoming treatment resistance -- Overcoming resistance mechanisms -- Ten-eleven translocation 1 -- Ring-finger protein 43 -- Nuclear receptor coactivator 3 -- Large tumor suppressor -- Neurogenic locus notch homolog protein 3 -- Cyclic-AMP response element binding protein -- Remodeling the tumor microenvironment -- Combinational therapies and efforts to tailor therapy for individualized treatment -- Challenges and limitations -- Future directions and perspectives -- Opportunities in implementing innovative approaches and optimizing therapeutic outcomes -- Reshaping the landscape of colorectal cancer management -- Conclusion -- Conflict of Interest -- References -- 8 Splicing-associated drug resistance in colorectal cancer: targeting splicing signatures -- Abbreviations -- Introduction -- Alternate splicing events in colon cancer -- Cis regulatory elements -- Transregulatory factors in colorectal cancer -- Posttranslational alterations of transregulatory splicing factors -- Alternative splicing in drug resistance in colorectal cancer -- DNA damage response -- Resistance to apoptosis -- Invasion and metastasis -- Altering angiogenesis -- Targeting alternative splicing to reverse drug resistance -- Antisense oligonucleotides -- Therapeutic approaches of small molecule inhibitors -- Conclusion -- Conflict of Interest -- References -- 9 Nanomedicine innovations: conquering colorectal cancer drug resistance -- Introduction -- Mechanisms of drug resistance in colorectal cancer -- Mechanism of action of nanoparticles. | |
| 520 | |a Colorectal Cancer Treatment Resistance: Mechanisms, Insights, Advances and Solutions provide insights, knowledge, and potential solutions for healthcare professionals, researchers, and individuals affected by colorectal cancer. | ||
| 650 | 0 | |a Colon (Anatomy) |x Cancer |x Treatment. | |
| 650 | 0 | |a Rectum |x Cancer |x Treatment. | |
| 650 | 0 | |a Drug resistance in cancer cells. | |
| 650 | 2 | |a Drug Resistance, Neoplasm |0 (DNLM)D019008 | |
| 650 | 6 | |a Cellules cancéreuses |x Résistance aux médicaments. |0 (CaQQLa)201-0217335 | |
| 650 | 7 | |a Colon (Anatomy) |x Cancer |x Treatment |2 fast |0 (OCoLC)fst00868415 | |
| 650 | 7 | |a Drug resistance in cancer cells |2 fast |0 (OCoLC)fst00898703 | |
| 650 | 7 | |a Rectum |x Cancer |x Treatment |2 fast |0 (OCoLC)fst01091968 | |
| 700 | 1 | |a Dlamini, Zodwa. | |
| 856 | 4 | 0 | |3 ScienceDirect |u https://www.sciencedirect.com/science/book/9780443334757 |